Healthcare markets reacted sharply to US drug-pricing reforms, though selective positioning within smaller-cap healthcare and biotechnology companies supported fund performance.
Investors in T. Bailey’s funds of funds will be familiar with the Polar Capital Healthcare Opportunities Fund, a long-standing specialist thematic holding within the portfolios. Recent developments in the United States have once again put the healthcare sector in focus, with President Trump’s administration announcing sweeping reforms aimed at reducing drug prices. These have taken the form of “most favoured nation” price controls, direct government-negotiated discount deals, and tariffs for companies not expanding US production.
Such measures have unsettled global healthcare markets in recent months, triggering sharp volatility, particularly among large-cap pharmaceutical companies. Fortunately, the team at Polar Capital has been positioned for its fund to mitigate many of these policy risks, reducing exposure to major pharmaceutical names most vulnerable to price controls and tariffs, such as Eli Lilly and Novo Nordisk. Instead, the portfolio’s skew has been to small and mid-cap healthcare companies, as well as selective positions in biotechnology, medical equipment and generic drug manufacturers - areas with stronger growth potential and less exposure to US regulatory intervention.
Despite near-term volatility, the Polar Capital team note the sector’s valuation is at historic lows, and argue that negative sentiment and policy worries have created opportunities for patient investors. The sector’s operational strength, innovation pipeline, and long-term structural drivers remain intact. Indeed, any easing of political headwinds could be a catalyst for a strong recovery in healthcare shares.
To that end, the story continued this week with the White House reaching a deal with Pfizer to lower prices on multiple drugs in exchange for an exemption on looming tariffs. Under the deal, many of Pfizer’s drugs will be offered at steep discounts through a government-endorsed direct-to-consumer website called TrumpRx, set to launch in early 2026. This model is now being pushed as a template for future deals with other pharma companies and has eased investor fears of a costly trade war, thus benefiting the entire sector. As a result, the Polar Capital Healthcare Opportunities Fund was the strongest performing holding across the T. Bailey funds of funds last week, returning 6.3%.
The Polar Capital Healthcare Opportunities Fund continues to provide diversified exposure to the global healthcare opportunity set, while avoiding the areas most vulnerable to US political risk. The portfolio is positioned to capitalise on sector innovation, demographic tailwinds, and potential M&A, all while maintaining strong valuation discipline. With much bad news already discounted, the risk-reward for patient investors is attractive and we remain confident in the benefits of this specialist holding within the T. Bailey fund of funds approach.
